Expression of arginase II in prostate cancer.

Expression of arginase II in prostate cancer. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Expression of arginase II in prostate cancer. Abstract Text:

Shannon M Mumenthaler,Hong Yu,Sheila Tze,Stephen D Cederbaum,Anthony E Pegg,David B Seligson,Wayne W Grody,

Previous reports have shown elevated arginase activity in prostate cancer patients. This study was designed to compare expression levels of arginase II (AII) in various human prostate cancer cell lines and tissues. Expression levels of AII and other enzymes involved in arginine metabolism were examined in androgen-dependent (LNCaP, LAPC-4) and androgen-independent (PC3, DU145, CL-1, CL-2) prostate cancer cell lines by real-time RT-PCR and Western blot analysis. Further expression analysis of AII was accomplished by immunohistochemical staining of a tissue microarray comprised of 246 primary prostatectomy specimens. In addition, polyamine levels were measured within the prostate cancer cell lines by HPLC. Total polyamines were significantly lower in the androgen-dependent cell lines compared to the androgen-independent cell lines. AII expression was found to be most prominent in the androgen-dependent cell lines and least prominent in the androgen-independent cell lines. Additionally, we found expression of ornithine aminotransferase (OAT), an enzyme also responsible for ornithine production, to be inversely correlated with AII expression. The tissue microarray data revealed that the highest AII expression was seen in BPH, followed by PIN and normal samples, with the lowest expression levels observed in prostate cancer tissues. Moreover, we observed an expression gradient across Gleason grades revealing stronger AII expression in low-grade tumors. The polyamine data, combined with the expression analysis studies, support a possible correlation between AII, OAT, and polyamine synthesis. Based on these results, arginase II expression may play a role in prostate cancer progression. More specifically, the elevated AII expression seen in androgen-dependent and in more differentiated prostate cancers suggests that AII could be a potentially useful marker of early stage prostate adenocarcinoma.

Expression of arginase II in prostate cancer. Publishing Authors By Initials

SM Mumenthaler,H Yu,S Tze,SD Cederbaum,AE Pegg,DB Seligson,WW Grody,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Expression of arginase II in prostate cancer. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: International journal of oncology

VOLUME: 32

Page Numbers: 357-65

Journal Abbreviation: Int. J. Oncol.

ISSN: 1019-6439

DAY: 18

MONTH: Feb

YEAR: 2008

Expression of arginase II in prostate cancer. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 9306042

Expression of arginase II in prostate cancer. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Expression of arginase II in prostate cancer. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Expression of arginase II in prostate cancer.

AFFILIATION: Department of Pathology and Laboratory Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095-1732, USA.

Country: Greece

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Int J Oncol

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Expression of arginase II in prostate cancer Related Publications

• Contrasting features of urea cycle disorders in human patients and knockout mouse models.
• Disruption of arginase II alters prostate tumor formation in TRAMP mice.
• Expression of arginase II in prostate cancer.
• Increased plasma and tissue guanidino compounds in a mouse model of hyperargininemia.
• Keeping up with the next generation: massively parallel sequencing in clinical diagnostics.
• Polyamine homeostasis in arginase knockout mice.
• Understanding and treating "first-episode" schizophrenia.